"Flecainide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
| Descriptor ID |
D005424
|
| MeSH Number(s) |
D03.383.621.270
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Flecainide".
Below are MeSH descriptors whose meaning is more specific than "Flecainide".
This graph shows the total number of publications written about "Flecainide" by people in this website by year, and whether "Flecainide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Flecainide" by people in Profiles.
-
"Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide. J Cardiovasc Electrophysiol. 2021 08; 32(8):2207-2215.
-
Localized basal left ventricular dyssynchrony induced by manifest accessory pathway: Successful differentiation from cardiac involvement of sarcoidosis with administration of flecainide acetate. J Electrocardiol. 2019 Nov - Dec; 57:87-89.
-
Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture. Am J Case Rep. 2019 Aug 30; 20:1279-1283.
-
Flecainide-Induced Left Ventricular Dysfunction: Fact or Fiction? Cardiovasc Toxicol. 2017 10; 17(4):494-495.
-
In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. J Physiol. 2016 Feb 01; 594(3):567-93.
-
Flecainide use in children with cardiomyopathy or structural heart disease. Pediatr Cardiol. 2015 Jan; 36(1):146-50.
-
A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents. J Cardiovasc Electrophysiol. 2007 Apr; 18(4):434-40.
-
Safe and effective pharmacologic management of arrhythmias. Tex Heart Inst J. 2005; 32(2):209-11.
-
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age. J Am Coll Cardiol. 2002 Feb 06; 39(3):517-20.
-
Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation. 2000 Aug 22; 102(8):921-5.